Eton Q4 2023 Earnings Report
Key Takeaways
Eton Pharmaceuticals reported a strong fourth quarter, marked by a 109% increase in product sales and royalty revenue. The company achieved positive operating cash flow and saw favorable developments in its pipeline, including positive study results for ET-400 and ET-600.
Reported a 109% year-over-year increase in product sales and royalty revenue, reaching $7.3 million.
Achieved positive operating cash flow of $0.4 million.
ET-400 passed pivotal bioequivalence study, with NDA submission expected in Q2 2024.
ET-600 passed pilot bioequivalence study; pivotal study planned for the second half of 2024.
Eton
Eton
Eton Revenue by Segment
Forward Guidance
Eton anticipates continued growth of product sales in 2024 and looks forward to submitting an NDA for ET-400 in the second quarter of this year and ET-600 early next year.
Positive Outlook
- Continued growth of product sales is anticipated in 2024.
- NDA submission for ET-400 is expected in Q2 2024.
- Potential FDA approval for ET-400 as early as Q1 2025.
- Pivotal study for ET-600 is planned for the second half of 2024, with potential NDA submission in early 2025.
- Ultra-rare disease product Nitisinone capsules launched in February 2024.